Switching to an alternative biological agent in juvenile idiopathic arthritis (I)
نویسندگان
چکیده
منابع مشابه
Switching to an alternative biological agent in juvenile idiopathic arthritis (I)
Results The sample included 83 girls and 26 boys aged 10 ± 4.4 (2.4-19.6) with a disease duration of 5 ± 3.4 (0.117) years. The initial biological agent was etanercept (ETA) in 87 cases, adalimumab (ADA) in 9, anakinra (AK) in 12 and infliximab (IFX) in 1. Twenty-eight patients switched to a second biological agent, 7 to a third and 2 to a fourth. Switching was due to inefficacy since adverse e...
متن کاملSwitching to an alternative biological agent in juvenile idiopathic arthritis (II)
Methods This is a retrospective study of 109 JIA patients from a tertiary centre (see poster 1). Variables included were: current biological treatment (both the first agent used as the second, third or fourth when it had been switched) and duration of treatment (years with a new agent or since reintroduction of an agent used before) plus physician visual analogue scale (ph-VAS), erythrocyte sed...
متن کاملMulticentric Carpotarsal Osteolysis Mimicking Juvenile Idiopathic Arthritis
Background Multicentric carpotarsal osteolysis (MCTO), a skeletal dysplasia presents in early childhood mimicking juvenile idiopathic arthritis (JIA). Recognition of this syndrome is essential to avoid unnecessary treatment with immunosuppressive agents because of different course and treatment. Case Report A 3-year-old boy presented with swelling and restriction of right wrist joint and left ...
متن کاملPReS-FINAL-2133: Drug survival and switching of biological agents in systemic juvenile idiopathic arthritis
Methods A retrospective observational study was conducted on SJIA patients treated in a French pediatric rheumatology reference center using the CEMARA register, a nationwide information system for rare diseases. We included patients who started biotherapy between 2005 and 2012 with a follow-up of at least 6 months after treatment initiation. Factors for switching or discontinuation of a biolog...
متن کاملRenal disorder and biological treatment in juvenile idiopathic arthritis
Results The patient was diagnosed with Juvenile Idiopathic Arthritis when she was 3 years and 2 months old, for which she was first treated with nonsteroidal antiinflamatory drugs, then DMARDS (Methotrexate), but without a very good course of the disease. When she reached the age of 4 years and 5 months she started biological treatment, with a good response clinically and of the laboratory test...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Rheumatology
سال: 2011
ISSN: 1546-0096
DOI: 10.1186/1546-0096-9-s1-p162